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Abstract
High-grade neuroepithelial tumor with BCOR exon 15 internal tandem duplication (HGNET 
BCOR ex15 ITD) is a recently proposed tumor entity of the central nervous system (CNS) with a 
distinct methylation profile and characteristic genetic alteration. The complete spectrum of 
histologic features, accompanying genetic alterations, clinical outcomes, and optimal treatment for 
this new tumor entity are largely unknown. Here, we performed a comprehensive assessment of 
ten new cases of HGNET BCOR ex15 ITD. The tumors mostly occurred in young children and 
were located in the cerebral or cerebellar hemispheres. On imaging all tumors were large, well-
circumscribed, heterogeneous masses with variable enhancement and reduced diffusion. They 
were histologically characterized by predominantly solid growth, glioma-like fibrillarity, 
perivascular pseudorosettes, and palisading necrosis, but absence of microvascular proliferation. 
They demonstrated sparse to absent GFAP expression, no synaptophysin expression, variable 
OLIG2 and NeuN positivity, and diffuse strong BCOR nuclear positivity. While BCOR exon 15 
internal tandem duplication was the solitary pathogenic alteration identified in six cases, four cases 
contained additional alterations including CDKN2A/B homozygous deletion, TERT amplification 
or promoter hotspot mutation, and damaging mutations in TP53, BCORL1, EP300, SMARCA2, 
and STAG2. While the limited clinical follow-up in prior reports had indicated a uniformly dismal 
prognosis for this tumor entity, this cohort includes multiple long-term survivors. Our study further 
supports inclusion of HGNET BCOR ex15 ITD as a distinct CNS tumor entity and expands the 
known clinicopathologic, radiographic, and genetic features.
INTRODUCTION
A recent genomic profiling study of tumors previously diagnosed as primitive 
neuroectodermal tumor of the central nervous system (CNS-PNET) identified a new subtype 
of high-grade neuroepithelial tumor unified by a recurrent internal tandem duplication 
within exon 15 of the BCOR transcriptional co-repressor gene and a distinct genome-wide 
methylation profile compared to all other CNS tumor entities assessed to date (26). These 
tumors (hereafter abbreviated HGNET BCOR ex15 ITD) predominantly arose in the 
cerebral or cerebellar hemispheres of young children, had an approximately equal male to 
female distribution, were histologically characterized by perivascular pseudorosettes and 
glioma-like fibrillarity, and had poor outcomes in the small number of cases with available 
clinical follow-up.
The protein product of the BCOR gene was initially identified in 2000 as a novel binding 
partner of BCL6, which is a POZ/zinc finger domain-containing transcriptional repressor 
protein (9). BCOR was demonstrated to function as a transcriptional co-repressor when 
tethered to DNA that potentiated BCL6 mediated repression, specifically through its 
association with class I and II histone deacetylases (9). Inherited/constitutional mutations in 
the BCOR gene were identified in 2004 as the cause of an X-linked oculofaciocardiodental 
syndrome (Online Mendelian Inheritance in Man #300166) characterized by 
microphthalmia, congenital cataracts, long narrow face, dental radiculomegaly with 
persistent primary teeth, and cardiac septal defects (15). Studies in osteodentinogenic 
mesenchymal stem cells from a patient with oculofaciocardiodental syndrome found that 
BCOR mutation disrupted homeostasis by resulting in increased methylation of lysine 4 and 
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lysine 36 on the tail of histone H3, thereby reactivating transcription of silenced target genes 
(6). Thus, BCOR appears to be a critical epigenetic regulatory gene whose constitutional 
disruption results in a severe developmental syndrome affecting multiple organ systems.
Whereas constitutional mutations in the BCOR gene perturb organogenesis during 
development, somatic alterations in BCOR have now been identified as recurrent genetic 
drivers in a wide spectrum of human tumor types. A recurrent internal tandem duplication 
within exon 15 of BCOR has been identified as the defining genetic alteration in clear cell 
sarcoma of the kidney, primitive myxoid mesenchymal tumor of infancy, and a subset of 
CNS high-grade neuroepithelial tumors (2, 10, 23, 26, 24, 28). Distinct from exon 15 
internal tandem duplication, in-frame gene fusions involving the BCOR gene are present in a 
subset of endometrial stromal sarcomas, pediatric low-grade gliomas, and undifferentiated 
round cell sarcomas of bone and soft tissue, most often with the ZC3H7B gene in 
endometrial stromal sarcomas, the EP300 gene in pediatric low-grade gliomas, and the 
CCNB3 gene in bone and soft tissue sarcomas (13, 18, 20, 21, 25, 27). Lastly, somatic 
truncating mutations or homozygous deletions of BCOR have been recurrently found in 
acute myeloid leukemia, retinoblastoma, medulloblastoma, and diffuse gliomas (5, 8, 12, 14, 
16, 22, 29). Thus, the BCOR gene appears to be an important oncogenic driver in a broad 
spectrum of human tumor types, with distinct genetic alterations specific to different tumor 
entities.
Only a few additional patients with HGNET BCOR ex15 ITD have been reported since the 
initial description of this tumor entity by Sturm et al (1, 19, 26, 30). As such, the full 
spectrum of histologic features, accompanying genetic alterations, clinical outcomes, and 
optimal treatment for this new tumor entity remain largely undefined. Here, we report our 
experience with the clinical, radiographic, histologic, ultrastructural, and genetic features of 
ten new cases of HGNET BCOR ex15 ITD.
METHODS
Patient cohort
Ten children diagnosed with high-grade neuroepithelial tumors found to harbor BCOR exon 
15 internal tandem duplication by targeted next-generation sequencing analysis at UCSF 
Medical Center were included in this study. Patient SF-BCOR-2 has been previously 
reported in part (11). Pre-operative imaging studies were reviewed for each patient by two 
expert neuro-radiologists (M.A. and S.C.). This study was approved by the Committee on 
Human Research of the University of California, San Francisco, with a waiver of patient 
consent.
Tumor samples and histology review
All tumor specimens were fixed in 10% neutral-buffered formalin and embedded in paraffin. 
Pathologic review of all tumors was conducted by a group of expert neuropathologists 
(S.P.F., M.P., A.W.B., T.T., A.P., and D.A.S.).
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Immunohistochemistry
Immunohistochemistry was performed on whole formalin-fixed, paraffin-embedded tissue 
sections using the following antibodies: glial fibrillary acidic protein (GFAP, Dako, cat# 
GA524, polyclonal, 1:3000 dilution, 15 min incubation); oligodendrocyte transcription 
factor 2 (OLIG2, Immuno Bio Labs, polyclonal, 1:200 dilution, 30 min incubation); NeuN 
(Chemicon, cat# MAB377, clone A60, 1:4000 dilution, 15 min incubation); synaptophysin 
(Cell Marque, cat# 336A, polyclonal, 1:100 dilution, 30 min incubation); neurofilament 
(Cell Marque, cat# 302M, clone 2F11, undiluted, 30 min incubation); epithelial membrane 
antigen (EMA, Leica, cat# PA0035, clone GP1.4, undiluted, 15 min incubation); BCOR 
(Santa Cruz Biotechnology, cat# sc-514576, clone C-10, 1:200 dilution, 30 min incubation); 
p53 (Leica, cat# PA0057, clone DO-7, undiluted, 15 min incubation); Ki67 (Dako, cat# 
GA626, clone MIB1, 1:50 dilution, 30 min incubation). All immunostaining was performed 
on a Leica Bond-III automated stainer. ER1 antigen retrieval was used for OLIG2, 
neurofilament, NeuN, and EMA antibodies. ER2 antigen retrieval was used for 
synaptophysin, BCOR, p53, and Ki67 antibodies. No antigen retrieval was performed for 
GFAP. Diaminobenzidine was used as the chromogen, followed by hematoxylin 
counterstain.
Electron microscopy
Ultrathin (80 nm) sections of glutaraldehyde-fixed, Epon-embedded tissue were stained with 
2% uranyl acetate at the UCSF Electron Microscopy Core Lab. Sections were subsequently 
examined in a JEOL 1400 transmission electron microscope at 120 kV. Images were 
recorded with a Gatan SC1000 CCDE camera.
Targeted next-generation sequencing
Genomic DNA was extracted from formalin-fixed, paraffin-embedded blocks of tumor tissue 
from the ten tumors using the QIAamp DNA FFPE Tissue Kit (Qiagen). In nine cases, tumor 
tissue from the initial resection was used for sequencing analysis. The tumor tissue analyzed 
for patient SF-BCOR-8 was from the recurrent tumor following initial gross total resection, 
60 Gy cranial radiation, and adjuvant chemotherapy with temozolomide and bevacizumab. 
Genomic DNA was also extracted from a peripheral blood sample for four patients (SF-
BCOR-1, SF-BCOR-2, SF-BCOR-5, and SF-BCOR-7) using the QIAamp DNA Blood Midi 
Kit (Qiagen). Capture-based next-generation DNA sequencing was performed using an 
assay that targets all coding exons of 479 cancer-related genes, select introns and upstream 
regulatory regions of 47 genes to enable detection of structural variants including gene 
fusions, and DNA segments at regular intervals along each chromosome to enable genome-
wide copy number and zygosity analysis, with a total sequencing footprint of 2.8 Mb 
(UCSF500 Cancer Panel; Supplementary Table 1; reference 11). Multiplex library 
preparation was performed using the KAPA Hyper Prep Kit (Roche) according to the 
manufacturer’s specifications using 250 ng of sample DNA. Hybrid capture of pooled 
libraries was performed using a custom oligonucleotide library (Nimblegen SeqCap EZ 
Choice). Captured libraries were sequenced as paired-end 100 bp reads on an Illumina 
HiSeq 2500 instrument. Sequence reads were mapped to the reference human genome build 
GRCh37 (hg19) using the Burrows-Wheeler aligner (BWA). Recalibration and deduplication 
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of reads was performed using the Genome Analysis Toolkit (GATK). Coverage and 
sequencing statistics were determined using Picard CalculateHsMetrics and Picard 
CollectInsertSizeMetrics. Single nucleotide variant and insertion/deletion mutation calling 
was performed with FreeBayes and PinDel. Structural variant calling was performed with 
Delly. Variant annotation was performed with Annovar. Single nucleotide variants and 
insertions/deletions were visualized and verified using Integrated Genome Viewer. Genome-
wide copy number analysis based on on-target and off-target reads was performed by 
CNVkit and visualized using Nexus Copy Number (Biodiscovery).
Clinical summary and Kaplan-Meier survival analysis
Kaplan-Meier survival analysis was performed using GraphPad Prism software. In addition 
to the ten patients from this cohort, all previously reported cases of high-grade 
neuroepithelial tumors with confirmed BCOR exon 15 internal tandem duplication by 
targeted Sanger or next-generation sequencing were included in the clinical summary and 
survival analysis in Figure 10. These included 15 cases from Sturm et al, 6 cases from 
Yoshida et al, 3 cases from Appay et al, and 1 case from Paret et al (1, 19, 26, 30). The 
clinical features and data source of these previously reported 25 patients are shown in 
Supplementary Table 9. This analysis excluded the 19 cases from Sturm et al that clustered 
with “CNS high-grade neuroepithelial tumor with BCOR alteration” but did not have genetic 
analysis confirming BCOR exon 15 internal tandem duplication (26).
RESULTS
Clinical features
The three male and seven female patients ranged from 1–13 years old (median 3 years) at 
time of initial diagnosis (Table 1 and Supplementary Table 2). Seven tumors were in young 
children less than 5 years old, while three tumors were in older children. Presenting 
symptoms were variable ranging from headaches to seizures to focal neurologic deficits. 
Tumors were located in the cerebral hemispheres in five patients, in the cerebellar 
hemispheres in four patients, and in the basal ganglia in one patient. The cerebellar tumors 
were exclusively present in young children less than 5 years old, while the supratentorial 
tumors were present in both young and older children.
Imaging features
Pre-operative magnetic resonance imaging revealed solid, well-circumscribed masses in 
each of the ten patients (Figure 1 and Supplementary Table 3). The tumors were all large 
with associated mass effect. Maximal dimension ranged from 3.8 to 10.2 cm. Many of the 
tumors demonstrated central areas of necrosis or blood products. Contrast enhancement was 
variable but never showed the ring-enhancing pattern characteristic of most glioblastomas. 
Diffusion weighted imaging often showed reduced diffusion suggestive of high cellularity 
neoplasms. Most tumors abutted the overlying dura without definite invasion. No 
cerebrospinal dissemination was seen at time of diagnosis in any of the patients.
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Histologic features
The ten tumors all demonstrated a predominantly solid growth pattern with a sharp border 
with adjacent brain parenchyma, although a couple of tumors showed infiltration at their 
interface with adjacent brain (Figures 2-4, Table 3, and Supplementary Table 4). A 
prominent feature uniformly seen in all tumors was ependymoma-like perivascular 
pseudorosettes with tumor cells aggregated around blood vessels with an intervening 
anuclear zone; however, in contrast to ependymoma, the perivascular processes were 
negative for GFAP (see below). The tumor cells were characterized by round to oval nuclei 
with fine chromatin. Most examples demonstrated glioma-like fibrillarity. Necrosis was 
observed in all tumors, almost always with palisading of the tumor cells at the periphery. All 
tumors were highly vascular with a rich branching capillary network. However, well-
developed microvascular proliferation was not identified in any of the ten cases. Cellularity 
and mitotic activity was variable, ranging from areas with low cellularity and scant mitoses 
to densely cellular areas with numerous mitoses. Some of the tumors had a myxoid and 
microcystic background, while others had marked stromal and perivascular hyalinization 
reminiscent of astroblastoma. Microcalcifications were seen in a minority of cases. 
Rosenthal fibers and eosinophilic granular bodies were not observed in any of the tumors. 
Three cases featured distinctive Homer Wright-like rosettes, with tumor cells rosetted 
around central areas of eosinophilic fibrillar processes; this often raised a differential 
diagnostic consideration of medulloblastoma or other embryonal neoplasms. However, both 
the tumor cells and central cores of these rosettes lacked synaptophysin expression (see 
below), differentiating them from true Homer Wright (neuroblastic) rosettes.
Immunohistochemical features
Immunostaining for GFAP was negative in all or the vast majority of tumor cells in the nine 
evaluated cases (Figure 5 and Table 3). However, OLIG2 positivity was observed in most 
tumors, with variable labeling ranging from 10–40% of tumor cells. NeuN positivity was 
also observed in most tumors, with variable labeling of tumor nuclei ranging from 10–80%. 
Synaptophysin labeling was uniformly negative in the nine evaluated tumors. 
Immunohistochemistry for neurofilament protein often show scattered cells with 
cytoplasmic staining. Immunostaining for epithelial membrane antigen (EMA) was typically 
negative or showed faint granular cytoplasmic staining, distinct from the dot-like or ring-like 
staining pattern typically seen in ependymomas. Diffuse strong nuclear staining for BCOR 
protein was observed in the eight evaluated cases. The Ki-67 labeling index was variable 
ranging from 15–60% in the highest areas.
Ultrastructural features
Transmission electron microscopy was performed on two of the tumors (SF-BCOR-1 and 
SF-BCOR-7). This analysis showed primitive cells with abundant rough endoplasmic 
reticulum and limited intermediate cytoskeletal filaments (Figure 6). No tight junctions, 
cilia, or microvilli characteristic of ependymoma were seen. Additionally, no neurosecretory 
granules or synaptic vesicles were seen.
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Targeted next-generation sequencing results
Targeted next-generation sequencing of approximately 500 cancer-associated genes and 
genome-wide copy number analysis was performed on the ten tumors as described in the 
Methods. A tandem duplication within exon 15 of the BCOR gene was identified in all ten 
cases (Figures 7-8, Supplementary Table 5). The minimally duplicated codons across all ten 
tumors were p.L1713_G1738 (RefSeq transcript NM_001123385).
In six cases, the BCOR exon 15 internal tandem duplication was the solitary pathogenic 
alteration identified. Four cases contained additional genetic alterations considered likely to 
be contributing to tumor pathogenesis (Supplementary Tables 6 and 7). These included SF-
BCOR-9 with TERT promoter hotspot mutation and a splice site mutation in the SMARCA2 
chromatin remodeling gene. SF-BCOR-6 contained an additional truncating frameshift 
mutation in the CREBBP histone acetyltransferase gene, while SF-BCOR-10 contained a 
damaging missense mutation in the TP53 tumor suppressor gene. The genomic profiling that 
was performed for patient SF-BCOR-8 was on the recurrent tumor following initial gross 
total resection, 60 Gy cranial radiation, and adjuvant chemotherapy with temozolomide and 
bevacizumab. This recurrent tumor SF-BCOR-8 harbored BCOR exon 15 internal tandem 
duplication along with additional CDKN2A/B homozygous deletion, TERT promoter 
hotspot mutation (c.−124C>T), two truncating frameshift mutations in the BCORL1 gene, 
and a splice site mutation in the STAG2 gene. Whether any of these alterations were present 
in the initial tumor versus acquired during disease progression after therapy is unknown.
The somatic mutation burden was uniformly very low (less than 2 somatic mutations per Mb 
within the 2.8 Mb of the tumor genome that was interrogated by the sequencing assay). 
Among the four patients in which a normal sample was also sequenced, no pathogenic 
germline alterations associated with increased cancer risk were identified.
Five of the tumors demonstrated a balanced diploid genome without chromosomal gains or 
losses (Supplementary Table 8). Three of the tumors demonstrated a paucity of 
chromosomal gains/losses (fewer than 4). Two of the tumors (SF-BCOR-9 and SF-
BCOR-10) demonstrated markedly aneuploid genomes with numerous chromosomal gains 
and losses, both at time of initial resection in the absence of prior therapy. No recurrent 
chromosomal gains or losses in more than two of the ten tumors were observed.
Anaplastic features in HGNET BCOR exon 15 ITD
Case SF-BCOR-10 demonstrated two distinct histologic components (Figure 9). One was a 
lower grade appearing component with moderate cellularity, abundant fibrillarity, numerous 
calcifications, and scant mitoses. This was apposed to an overtly anaplastic component 
featuring dense cellularity, increased nuclear pleomorphism, and brisk mitotic activity. The 
anaplastic component was sharply demarcated from the lower grade component enabling 
genomic profiling to be performed separately on the two regions. Both components 
contained the identical BCOR exon 15 internal tandem duplication and a damaging missense 
mutation in the TP53 tumor suppressor gene. The lower grade component had monosomy 
13q as the solitary chromosomal copy number alteration, whereas the anaplastic component 
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harbored numerous chromosomal gains and losses (+1p, +1q [4N], +2, +6, +7, +12, +14q, 
+15q, +17, +18 [4N], +19, +21q [4N], and +22q).
Clinical outcomes
The complete clinical data including extent of resection, treatment regimen, and outcome 
data from the ten patients are presented in Table 1 and Supplementary Table 2. All ten 
patients initially underwent gross total resection. Four children were subsequently treated 
with cranial radiation, two children with craniospinal radiation with a boost to the tumor 
bed, and four children did not receive radiation as part of their immediate post-resection 
therapy. The initial chemotherapy regimen was temozolomide and bevacizumab following a 
high-grade glioma therapy protocol for three children, while six children were initially 
treated with an intensive multiagent chemotherapy regimen following an embryonal tumor 
therapy protocol. One child (SF-BCOR-4) did not receive any adjuvant radiation or 
chemotherapy following initial resection.
Clinical follow-up for this cohort of ten children ranged from 0.4 to 14.2 years (median 2.0 
years). Four children experienced tumor recurrence at 4, 14, 31, and 49 months after initial 
resection. The earliest recurrence at 4 months was in the child who did not receive any 
adjuvant therapy (SF-BCOR-4), who later developed disseminated disease along the spinal 
cord at 20 months after initial diagnosis. Two of the other children who experienced 
recurrence at 31 and 49 months had been treated with cranial radiation and chemotherapy 
following a high-grade glioma therapy protocol with temozolomide and bevacizumab (SF-
BCOR-8 and SF-BCOR-9). The fourth child who experienced recurrence at 14 months (SF-
BCOR-1) had not received radiation therapy but was treated with platinum-based multiagent 
chemotherapy following an embryonal tumor therapy protocol. These four children all 
underwent a second resection confirming tumor recurrence, followed by additional radiation 
and/or chemotherapy. The recurrent disease in these four children was localized (adjacent to 
the prior resection cavity), with only one patient in this cohort later experiencing 
cerebrospinal dissemination (SF-BCOR-4). All of the ten children in this cohort were alive 
at last clinical follow-up, including two long-term survivors at 4.5 years (SF-BCOR-8) and 
14.2 years (SF-BCOR-1) after initial diagnosis.
We next curated clinical data from all reported cases of CNS high-grade neuroepithelial 
tumor with confirmed BCOR exon 15 internal tandem duplication (Supplementary Table 9). 
Patient age, sex, tumor location, and survival data were analyzed from the 10 patients in our 
cohort together with these 25 previously reported patients (Figure 10). The median patient 
age was 3.5 years (range 0–22 years) at time of initial diagnosis. These 35 patients included 
16 males and 19 females. Tumors were located in the cerebellar hemispheres (n=16), 
cerebral hemispheres (n=14), basal ganglia (n=1), brainstem (n=1), and cerebellopontine 
angle (n=1) (Figure 10A). No significant association of tumor location with patient age at 
diagnosis was apparent (Figure 10B). Kaplan-Meier analysis of overall survival in the 24 
patients with available data revealed a poor prognosis in general, although the number of 
cases with adequate follow-up remains limited (Figure 10C).
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Discussion
HGNET BCOR ex15 ITD is a recently proposed tumor entity of the central nervous system 
for which the clinicopathologic features have yet to be fully defined. Here, we have 
performed comprehensive clinicopathologic, radiographic, and genomic studies on a cohort 
of ten new cases. Together with the previously reported 25 cases in the scientific literature to 
date, our study better defines the distinctive radiographic and pathologic features that 
characterize this tumor entity, as well as providing detailed outcome data for children treated 
following either high-grade glioma or CNS embryonal tumor therapy protocols.
HGNET BCOR ex15 ITD usually presents as a large, well-circumscribed, heterogeneous 
mass with reduced diffusion and variable enhancement in the cerebral or cerebellar 
hemispheres. The majority arise in children younger than 5 years of age, but multiple cases 
in teenagers or young adults have now been observed. No sex predilection is apparent for 
this tumor entity, unlike other brain tumors entities such as astroblastoma-like 
neuroepithelial tumors with MN1 alteration that demonstrate a significant female 
predominance (26).
HGNET BCOR ex15 ITD can demonstrate a wide morphologic spectrum, but usually 
feature a distinctive set of histologic and immunohistochemical features that provide clues to 
the diagnosis prior to molecular testing. Common features are a mostly solid growth pattern, 
GFAP-negative perivascular pseudorosettes, and monotonous round to ovoid nuclei with fine 
chromatin. Also, the characteristic combination of palisading necrosis without microvascular 
proliferation is helpful to differentiate these tumors from glioblastoma. The tumors can 
resemble anaplastic ependymomas due to perivascular pseudorosettes, astroblastomas due to 
perivascular pseudorosettes and hyalinized/collagenous stroma, or diffuse gliomas due to 
glial-like fibrillarity and infiltrative areas at their periphery. Those that contain structures 
resembling Homer Wright rosettes may also mimic medulloblastoma or CNS 
neuroblastoma, but differ from these entities based on their lack of synaptophysin 
expression. These are some of the most likely diagnoses that HGNET BCOR ex15 ITD may 
have received in the past. However, HGNET BCOR ex15 ITD have an unusual 
immunohistochemical profile with dual OLIG2 and NeuN positivity, along with sparse to 
absent GFAP expression and no synaptophysin expression, that can be helpful in 
distinguishing these tumors from potential histologic mimics. For example, this pattern is 
distinct from anaplastic ependymomas (usually OLIG2 negative, GFAP positive, and EMA 
positive with paranuclear dot-like staining), astroblastomas (usually GFAP positive), and 
diffuse gliomas (usually GFAP positive and NeuN negative). Additionally, the strong nuclear 
positivity for BCOR in virtually all tumor cells may be another helpful clue. However, the 
specificity of diffuse strong nuclear BCOR expression for this tumor entity needs to be 
further evaluated. For example, the pediatric low-grade gliomas with EP300-BCOR fusion 
can also demonstrate diffuse strong nuclear BCOR expression (27), and we have observed 
diffuse strong nuclear BCOR expression in an astroblastoma-like neuroepithelial tumor with 
MN1 rearrangement that lacked BCOR exon 15 ITD (data not shown).
We believe these HGNET BCOR ex15 ITD are almost certainly of neuroepithelial origin 
(and therefore not sarcomas), based on the combination of their intraparenchymal location 
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within the brain, glioma-like fibrillarity, expression of OLIG2 and NeuN proteins, and 
absence of appreciable intercellular basement membrane deposition in most cases. While the 
identical BCOR exon 15 ITD is also present in two sarcoma entities, this most likely reflects 
a common molecular pathogenesis arising in distinct cells of origin: neural progenitor cell 
for HGNET BCOR ex15 ITD versus a mesenchymal progenitor cell for clear cell sarcoma of 
the kidney and primitive myxoid mesenchymal tumor of infancy. Future comparison of the 
genome-wide methylation and transcriptome profiles between the different tumor entities 
that all share the identical BCOR exon 15 ITD is likely to be informative in this regard.
While optimal treatment strategies remain uncertain for this tumor entity, the clinical data 
from this cohort do provide some new valuable insight. For instance, the one patient (SF-
BCOR-4) in this cohort who did not receive any adjuvant radiation or chemotherapy after 
gross total resection experienced rapid local recurrence and also subsequently cerebrospinal 
dissemination. In combination with the poor outcomes observed for most patients to date, 
we believe that additional adjuvant therapy beyond the maximal safest resection possible 
should be strongly considered in all patients. Among the three children in our cohort that 
were treated following a high-grade glioma therapy protocol with cranial radiation and 
adjuvant temozolomide plus bevacizumab, two experienced local recurrence within 4 years 
after initial resection, whereas the third patient remains recurrence-free at approximately 2 
years after initial resection. Among the six children in our cohort that were treated following 
a CNS embryonal tumor therapy protocol with intensive platinum-based chemotherapy 
regimens (three without radiation due to young patient age and three with cranial or 
craniospinal radiation), only one child experienced local recurrence at 14 months but is a 
long-term survivor who is currently alive without evidence of disease at 14 years after initial 
diagnosis. However, the follow-up interval is less than 2 years for the other five children, 
making the efficacy of this CNS embryonal tumor therapy protocol inconclusive at this 
point.
The high-grade neuroepithelial tumors in this cohort are all unified by the presence of an 
internal tandem duplication within exon 15 of the BCOR gene. This recurrent internal 
tandem duplication that is heterozygous (i.e. without loss of the remaining wildtype allele) 
and localizes within exon 15 that encodes the BCORL-PCGF1-binding domain is very likely 
to function as an activating, gain-of-function event. However, the specific mechanism by 
which this recurrent internal tandem duplication event in BCOR drives tumor development 
remains unknown, as are methods to therapeutically intervene using a precision medicine 
approach for these aggressive malignancies of childhood driven by BCOR exon 15 ITD.
Recent genomic investigation has revealed that distinct alterations in the BCOR gene are 
selected for in different brain tumor entities. Unlike the high-grade neuroepithelial tumors in 
this cohort defined by BCOR exon 15 ITD, a group of children with low-grade gliomas 
harboring in-frame EP300-BCOR gene fusions were recently reported that had divergent 
histologic features and a distinct genome-wide methylation profile compared to HGNET 
BCOR ex15 ITD (27). These gliomas with EP300-BCOR fusions had histologic features 
somewhat resembling either pilocytic astrocytoma or dysembryoplastic neuroepithelial 
tumor and lacked the perivascular pseudorosettes and palisading necrosis that characterize 
HGNET BCOR ex15 ITD. Additionally, truncating mutations or homozygous deletions of 
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BCOR or its homolog BCORL1 have been recurrently found in retinoblastoma, 
medulloblastoma, and diffuse gliomas (12, 14, 16, 22, 29). Among diffuse gliomas, 
truncating mutations or homozygous deletions in the BCOR or BCORL1 genes are present 
in a significant fraction of H3 K27M-mutant diffuse midline gliomas, as well as high-grade 
gliomas in the cerebral hemispheres of children (14, 29). In contrast to the exon 15 internal 
tandem duplication and in-frame fusion with EP300 that are likely activating gain-of-
function events, these recurrent nonsense or frameshift mutations as well as homozygous 
deletions in diffuse gliomas, medulloblastomas, and retinoblastomas are almost certainly 
functionally inactivating events. Thus, the oncogenic mechanisms by which BCOR 
alterations promote tumorigenesis are likely to be divergent dependent on the specific 
genetic alteration present. While Sturm et al initially proposed the terminology “CNS high-
grade neuroepithelial tumor with BCOR alteration”, it is now clear that the described entity 
was limited to those neuroepithelial tumors with exon 15 ITD and not merely any BCOR 
alteration (26). We thus recommend the more precise terminology of “CNS high-grade 
neuroepithelial tumor with BCOR exon 15 internal tandem duplication” for this tumor entity 
moving forward.
While the majority of cases in this patient cohort harbored BCOR exon 15 internal tandem 
duplication as the solitary pathogenic alteration, a subset harbored additional genetic 
alterations likely contributing to tumor pathogenesis. These were most frequently 
inactivating mutations within other transcriptional or epigenetic regulatory genes, including 
EP300, SMARCA2, STAG2, and BCORL1. Why these tumors selected for additional 
genetic alterations predicted to disrupt gene expression profiles beyond the BCOR exon 15 
ITD is uncertain. Additionally, two of the cases contained TERT alterations, one with gene 
amplification and one with promoter hotspot mutation, indicating that telomere maintenance 
in a subset of HGNET BCOR ex15 ITD is accomplished by TERT activation. However, 
none of the ten cases harbored ATRX mutation or deletion, indicating that the alternative 
lengthening of telomeres typical of IDH-mutant and histone H3-mutant diffuse gliomas is 
not common in HGNET BCOR ex15 ITD.
Notably, none of the cases contained IDH1 p.R132 or IDH2 p.R172 mutations that define 
diffuse lower-grade gliomas in the cerebral hemispheres of adults (4). None of the cases 
contained H3F3A or HIST1H3B p.K27M mutation that define the majority of diffuse 
gliomas within midline structures of the CNS (14, 29). H3F3A p.G34 mutation or SETD2 
truncating mutation that define a subset of high-grade gliomas in the cerebral hemispheres of 
teenagers and young adults were not present in any of the cases (7, 14). No cases contained 
amplification, mutation, or rearrangement of receptor tyrosine kinase genes such as EGFR, 
PDGFRA, MET, FGFR1–3, NTRK1–3, ALK, or ROS1 that are common in high-grade 
gliomas in children and adults (3, 14, 29). None of the cases contained BRAF mutation or 
rearrangement, nor any other alteration in components of the Ras-Raf-MAP kinase signaling 
pathway that are common in pediatric low-grade gliomas (31). None of the cases contained 
alterations in components of the PI3-kinase-Akt-mTOR signaling pathway including the 
PTEN, TSC1, TSC2, PIK3CA, or PIK3R1 genes that are common in multiple glioma 
subtypes (3, 14, 31). MYB or MYBL1 rearrangements that are common in pediatric low-
grade gliomas were not found in any of the cases (31). None of the cases contained MYC or 
MYCN amplification that are common in Group 3 and 4 medulloblastomas, as well as a 
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subset of pediatric glioblastomas (14, 16). Additionally, none of the cases contained RELA 
or YAP1 fusions or NF2 mutation that are common in ependymomas (17). None of the cases 
contained SMARCB1 or SMARCA4 biallelic inactivation that defines atypical teratoid/
rhabdoid tumor, although one tumor did harbor a heterozygous truncating mutation in the 
related SMARCA2 chromatin remodeling gene. Thus, HGNET BCOR ex15 ITD appear to 
be genetically distinct from all other CNS tumor entities that have been molecularly defined 
to date.
In summary, we have comprehensively characterized the new tumor entity “High-grade 
neuroepithelial tumor with BCOR exon 15 internal tandem duplication”. While the BCOR 
exon 15 ITD appears to be the solitary genetic driver in most cases, a subset also acquires 
additional genetic alterations that include TERT activation, CDKN2A homozygous deletion, 
and inactivating mutations in other transcriptional and epigenetic regulatory genes including 
EP300, SMARCA2, STAG2, and BCORL1. Rare examples may also acquire TP53 
mutational inactivation along with numerous chromosomal gains/losses that corresponds 
with histologic anaplasia. Future studies are warranted to identify the cellular mechanisms 
by which BCOR exon 15 ITD drives tumorigenesis and determine the optimal treatment 
strategies for affected children.
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Figure 1. Imaging features of the CNS high-grade neuroepithelial tumors with BCOR exon 15 
internal tandem duplication.
Shown are pre-operative magnetic resonance images for cases #1-9. All tumors were large, 
well-circumscribed, heterogeneous masses with variable enhancement and reduced 
diffusion. Many of the tumors demonstrated central areas of necrosis or blood products.
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Figure 2. Histologic features of the CNS high-grade neuroepithelial tumors with BCOR exon 15 
internal tandem duplication.
Shown are representative hematoxylin and eosin (H&E) stained sections of cases #1-9.
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Figure 3. Recurrent histologic features observed in CNS high-grade neuroepithelial tumor with 
BCOR exon 15 internal tandem duplication.
Shown are H&E stained sections demonstrating the circumscribed growth, palisading 
necrosis, perivascular pseudorosettes, and glioma-like fibrillarity frequently observed in this 
tumor entity.
Ferris et al. Page 17
Brain Pathol. Author manuscript; available in PMC 2021 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 4. Additional recurrent histologic features observed in a subset of CNS high-grade 
neuroepithelial tumor with BCOR exon 15 internal tandem duplication.
Shown are H&E stained sections demonstrating the microcystic/myxoid background, 
hyalinized stroma, areas with dense cellularity and brisk mitotic activity, and Homer Wright-
like rosettes observed in a subset of the cases.
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Figure 5. Immunohistochemical features of CNS high-grade neuroepithelial tumor with BCOR 
exon 15 internal tandem duplication.
Shown are representative immunohistochemical stains demonstrating the sparse to absent 
GFAP positivity, variable OLIG2 positivity, consistent NeuN positivity, synaptophysin 
negativity, granular cytoplasmic EMA staining with absence of paranuclear dot-like 
positivity, and diffuse strong nuclear BCOR expression.
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Figure 6. Ultrastructural features of CNS high-grade neuroepithelial tumor with BCOR exon 15 
internal tandem duplication.
Shown are electron microscopy images demonstrating primitive cells with abundant rough 
endoplasmic reticulum. No tight junctions, cilia, or microvilli characteristic of ependymal 
differentiation are seen. Additionally, no neurosecretory granules or synaptic vesicles are 
observed.
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Figure 7. Genetic landscape of CNS high-grade neuroepithelial tumor with BCOR exon 15 
internal tandem duplication.
Oncoprint table of the clinical features, likely pathogenic genetic alterations, and quantity of 
chromosomal copy number alterations in the ten cases.
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Figure 8. 
Diagram of the amino acid sequence at the C-terminus of the BCOR protein showing the 
duplicated amino acids within exon 15 for the ten CNS high-grade neuroepithelial tumors 
with BCOR exon 15 internal tandem duplication.
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Figure 9. Anaplastic features in CNS HGNET BCOR ex15 ITD (case #10) in association with 
TP53 inactivation and marked aneuploidy.
A,B. Pre-operative axial and coronal T2-weighted MR images showing a circumscribed 
mass in the right cerebral hemisphere. C,D,E. H&E stained sections showing a biphasic 
tumor composed of a lower grade appearing component with abundant fibrillar processes (C 
left, D), and an anaplastic component with dense cellularity, severe nuclear pleomorphism, 
and brisk mitotic activity (C right, E). F. Genome-wide copy number plots for the lower 
grade appearing component showing monosomy 13q as the solitary copy number alteration 
(top), and for the anaplastic component showing numerous chromosomal gains and losses 
(bottom).
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Figure 10. Clinical features of CNS high-grade neuroepithelial tumor with BCOR exon 15 
internal tandem duplication.
Clinical data from the ten patients in this cohort (Supplementary Table 2), as well as all 
previously reported cases of this tumor entity with confirmed BCOR exon 15 internal 
tandem duplication (Supplementary Table 9), were aggregated for analysis. A. Location of 
the 33 tumors with specified anatomic site in the central nervous system. B. Age at initial 
diagnosis stratified by location for the 32 tumors with specified age and anatomic site. C. 
Kaplan-Meier survival analysis for the 24 patients with available clinical outcome data.
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